Thrombosis Drug Market - Global Industry Analysis

Thrombosis Drug Market

Global Thrombosis Drug Market By Disease Type (Deep Vein Thrombosis, Pulmonary Embolism, and Atrial Fibrillation), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), By Drug Class (P2Y12 Platelet Inhibitor, Xa Inhibitor, and Heparin), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Published Date: 05-Apr-2022 Category: Pharmaceutical Report Format : PDF Pages: 180 Report Code: ZMR-3363 Status : Published

The global thrombosis drug market is likely to grow from $25,892 million in 2021 to $47,789 million by the end of 2028. It is likely to exhibit exponential growth with a healthy CAGR of 9.51% during the forecast period.

Description

Thrombosis Drug Market: Industry Perspective

The global thrombosis drug market is likely to grow from $25,892 million in 2021 to $47,789 million by the end of 2028. It is likely to exhibit exponential growth with a healthy CAGR of 9.51% during the forecast period. The report presents comprehensive projections on the growth factors, opportunities, and restraining factors.

Thrombosis Drug Market: Overview

Thrombosis drugs are referred to as the ones that inhibit the working of platelets, avoid clot formation, and further inhibit the formation of other new clots. These drugs help prevent myriad conditions like deep vein thrombosis and atrial fibrillation. Such drugs have many side effects like bleeding gums & noses, heavy menstrual periods, vomiting, and bleeding. Thrombosis treatment is used to cure the clots to avoid the blockage of an organ. The drugs adopted in the treatment of thrombosis are also referred to as blood thinners.

COVID-19 Impact:

The Covid-19 outbreak has led to a negative impact on the global thrombosis drug market because the primary concentration of government, healthcare centers, and pharmaceutical companies was to prioritize the treatment of coronavirus. They all took the initiative to prevent the spread of Covid-19 cases further. Therefore, they were engaged in the development of vaccines and drugs along with the focus on optimizing the medicine supply chain logistics. The whole healthcare sector prioritized the Covid treatment, and therefore other treatments were given secondary importance. Additionally, the research and development pipeline also concentrated on innovating anti-covid solutions. However, the surge in demand for drugs from the pharmaceutical and biotechnology sector is likely to throw strong growth prospects in the global market in the forthcoming years.

Global Thrombosis Drug Market

Thrombosis Drug Market: Growth Drivers

Increasing consumption of tobacco and liquor will drive the growth of the global market.

As per the report from the World Health Organization, it is found that one in three people is overweight. Such statistics are due to the increasing consumption of tobacco and liquor, which is likely to scale up the risk of obesity. Such a landscape further creates critical hypertension, which causes thrombosis-associated problems. Therefore, it is likely to fuel the growth of the global thrombosis drug market exponentially in the forthcoming years. Another crucial factor fueling the growth of the global market is the growing awareness among people regarding the importance of cardiovascular health. However, treating cardiovascular problems with medication is a multifaceted approach, but people are also adopting blood thinner medication as a critical treatment for their problems. Additionally, a number of manufacturers introduced many anticoagulants which address the issues associated with the prevention of blood clots. Such a market landscape will expand the scope of thrombosis drugs. Simultaneously, there is a spike in the number of cases associated with myocardial problems and coronary heart disease, which is also likely to contribute to the growth of the market.

Thrombosis Drug Market: Restraints

Lack of awareness among patients is likely to spur the growth of the global market.

Thrombosis is a result of certain cardiovascular problems due to aging, and nowadays, the geriatric population is growing rapidly. But simultaneously, there is a lack of awareness among people regarding the seriousness of thrombosis, which in turn will also hamper the growth of the global market.

Thrombosis Drug Market: Opportunities

Increasing geriatric population is likely to open new avenues in the global market.

Thrombosis is common in the aging population because it is caused due to cardiovascular problems, which are highly found in aged people. Additionally, the growing disposable income of people is further encouraging them to adopt complete and successful treatment, which is likely to expand the scope of the global market.

Thrombosis Drug Market: Challenges

Side effects of thrombosis drugs are a huge challenge in the global market.

For instance, the common side effect of such drugs is uncontrolled bleeding. Furthermore, anti-clotting medications often cause a stroke. Therefore, such conditions are likely to be a huge challenge in the global market.

Thrombosis Drug Market: Segmentation

The global thrombosis drug market can be segmented into disease type, distribution channel, drug class, and region.

By disease type, the market can be segmented into atrial fibrillation, pulmonary embolism, and deep vein thrombosis.

By distribution channel, the market can be segmented into retail pharmacies, hospital pharmacies, and online pharmacies.

By drug class, the market can be segmented into heparin, Xa inhibitor, and P2Y12 platelet inhibitor.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Recent Developments

  • Mylan N.V. revealed that it had signed an agreement to take over Aspen Pharmacare Holdings Ltd. in Europe in September 2020.
  • The Story Brook found that using anticoagulation solution lowers the mortality in severe cases of Covid-19 patients in February 2021.

Thrombosis Drug Market: Regional Landscape

North America to hold the largest market share.

North America swipes the largest share in the global thrombosis drug market due to the presence of well-established health infrastructure in the region. Additionally, the presence of proper reimbursement medical policies is further encouraging people to opt for complete thrombosis treatment. Furthermore, the presence of prominent market leaders will also expand the scope of the regional market.

Thrombosis Drug Market: Competitive Landscape

Some of the significant players in the global thrombosis drug market include Pfizer, Aspen Pharmacare Holdings Limited, Bayer AG, AstraZeneca plc, Sanofi, Johnson & Johnson, Bristol-Myers Squibb Company, Baxter International Inc., Boehringer Ingelheim GmbH, and GlaxoSmithKline plc.

Global thrombosis drug market is segmented as follows:

By Disease type

  • Deep vein thrombosis
  • Pulmonary embolism
  • Atrial fibrillation

By Distribution channel

  • Online pharmacies
  • Hospital pharmacies
  • Retail pharmacies

By Drug class

  • P2Y12 platelet inhibitor
  • Xa inhibitor
  • Heparin

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Free Analysis

Thrombosis is a condition in which blood gets a clot in the blood vessel, which leads to the obstruction of blood flow in the circulatory system and it may travel to the other body parts. Thrombosis drugs are those drugs which are used to treat the blood clots formed in the blood arteries and veins. These drugs generally include anticoagulant drugs and thrombin inhibitor drugs which dilute the blood and dissolve the blood clot in the arteries and veins and also reduce the chances of embolism. These drugs are available in the form of a capsule, tablet, and injection. As per the Center for Disease Control and Prevention report 2015, the exact number of people diagnosed with deep vein thrombosis or pulmonary embolism is not known, although it is estimated that 900,000 people could be affected (1 to 2 per 1,000) each year in the United States.

The major factors driving the growth of thrombosis drug market are increased the prevalence of thrombosis coupled with the availability of new products. As per the International Society on Thrombosis and Haemostasis report every year, there are approximately 10 million cases of venous thromboembolism recorded worldwide. There are various companies which are constantly working for the development of various new and effective drugs which is expected to provide better results as compared to conventional drugs. The companies have research and development department which helps in the development of these drugs and further launch of new drugs in the area of treatment are further expected to promote the growth of thrombosis treatment market. Moreover, unmet needs of people and significant technological advancements in the healthcare sectors and new product launches are expected to fuel the growth of thrombosis drug market. However, increased use of generic drugs is expected to hamper the growth of thrombosis drug market over the forecast period.

Global Thrombosis Drug Market

Thrombosis drug market is segmented on the basis of drug class such as Factor Xa Inhibitor, Low Molecular Weight Heparin, and P2Y12 Platelet Inhibitor. Factor Xa Inhibitor segment is expected to dominate the thrombosis drug market over the forecast period. Based on the indication, the thrombosis drug market is segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. Pulmonary embolism is expected to dominate the thrombosis drug market in the near future. Based on the distribution channel, the thrombosis drug market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Over the forecast period, hospital pharmacies are expected to dominate the thrombosis drug market.

Based on the region, the global thrombosis drug market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the thrombosis drug market in the near future which is closely followed by Europe owing to the various technological advancement and increased prevalence of thrombosis. The Asia Pacific is expected to expand moderately over the forecast period. Latin America and the Middle East & Africa are expected to develop considerably. 

Some of the major key players of thrombosis drug market include GlaxoSmithKline Plc., Aspen Pharmacare Holdings Limited, Johnson & Johnson, Sanofi, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Baxter International Inc., and Pfizer, Inc., among others.

FrequentlyAsked Questions

As per the report from the World Health Organization, it is found that one in three people is overweight. Such statistics are due to the increasing consumption of tobacco and liquor, which is likely to scale up the risk of obesity. Such a landscape further creates critical hypertension, which causes thrombosis-associated problems. Therefore, it is likely to fuel the growth of the global thrombosis drug market exponentially in the forthcoming years.

The global thrombosis drug market is likely to grow from $25,892 million in 2021 to $47,789 million by the end of 2028. It is likely to exhibit exponential growth with a healthy CAGR of 9.51% during the forecast period.

Some of the significant players in the global thrombosis drug market include Pfizer, Aspen Pharmacare Holdings Limited, Bayer AG, AstraZeneca plc, Sanofi, Johnson & Johnson, Bristol-Myers Squibb Company, Baxter International Inc., Boehringer Ingelheim GmbH, and GlaxoSmithKline plc.

North America swipes the largest share in the global thrombosis drug market due to the presence of well-established health infrastructure in the region. Additionally, the presence of proper reimbursement medical policies is further encouraging people to opt for complete thrombosis treatment.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed